Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by STEVEN G WAGUESPACK and NAIFA L BUSAIDY.
STEVEN G WAGUESPACK
Connection Strength
2.433
NAIFA L BUSAIDY
  1. Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma. Thyroid. 2024 Dec 04.
    View in: PubMed
    Score: 0.249
  2. Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-Term Outcomes in 144 Patients Over 6 Decades. J Clin Endocrinol Metab. 2024 Aug 13; 109(9):2256-2268.
    View in: PubMed
    Score: 0.244
  3. Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion-Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease? JCO Precis Oncol. 2022 04; 6:e2100467.
    View in: PubMed
    Score: 0.207
  4. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol. 2019 Aug; 145(8):1977-1986.
    View in: PubMed
    Score: 0.171
  5. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine. J Clin Endocrinol Metab. 2018 10 01; 103(10):3698-3705.
    View in: PubMed
    Score: 0.162
  6. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013 Jan; 98(1):31-42.
    View in: PubMed
    Score: 0.108
  7. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. 2010 Jun; 95(6):2588-95.
    View in: PubMed
    Score: 0.090
  8. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer: A Potential Strategy for Systemic Therapy Deferral. J Natl Compr Canc Netw. 2024 Dec 11; 1-7.
    View in: PubMed
    Score: 0.062
  9. Clinical course of atypical parathyroid neoplasm with soft tissue extension. J Surg Oncol. 2024 Oct; 130(5):1092-1096.
    View in: PubMed
    Score: 0.061
  10. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004 Aug; 26(8):716-26.
    View in: PubMed
    Score: 0.061
  11. Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness. J Endocr Soc. 2024 Apr 06; 8(6):bvae048.
    View in: PubMed
    Score: 0.059
  12. Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer. Head Neck. 2024 02; 46(2):328-335.
    View in: PubMed
    Score: 0.058
  13. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid. 2023 01; 33(1):129-132.
    View in: PubMed
    Score: 0.055
  14. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. Endocr Relat Cancer. 2021 06 02; 28(7):419-431.
    View in: PubMed
    Score: 0.049
  15. Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck. 2021 01; 43(1):E7-E12.
    View in: PubMed
    Score: 0.047
  16. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck. 2020 06; 42(6):1325-1328.
    View in: PubMed
    Score: 0.045
  17. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid. 2018 10; 28(10):1243-1251.
    View in: PubMed
    Score: 0.041
  18. Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions. Thyroid. 2018 10; 28(10):1301-1310.
    View in: PubMed
    Score: 0.041
  19. Effect of Tumor Size and Minimal Extrathyroidal Extension in Patients with Differentiated Thyroid Cancer. Thyroid. 2018 08; 28(8):982-990.
    View in: PubMed
    Score: 0.040
  20. Extrathyroidal Extension: Does Strap Muscle Invasion Alone Influence Recurrence and Survival in Patients with Differentiated Thyroid Cancer? Ann Surg Oncol. 2018 Oct; 25(11):3380-3388.
    View in: PubMed
    Score: 0.040
  21. Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol. 2018 May; 25(5):1395-1402.
    View in: PubMed
    Score: 0.039
  22. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2017 09 01; 102(9):3591-3599.
    View in: PubMed
    Score: 0.038
  23. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2016 12; 101(12):4871-4877.
    View in: PubMed
    Score: 0.035
  24. Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer. J Clin Endocrinol Metab. 2016 11; 101(11):4461-4467.
    View in: PubMed
    Score: 0.035
  25. Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. Thyroid. 2015 Oct; 25(10):1085-90.
    View in: PubMed
    Score: 0.033
  26. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine. 2016 Feb; 51(2):351-9.
    View in: PubMed
    Score: 0.033
  27. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab. 2015 Jan; 100(1):E77-81.
    View in: PubMed
    Score: 0.031
  28. RET fusion as a novel driver of medullary thyroid carcinoma. J Clin Endocrinol Metab. 2015 Mar; 100(3):788-93.
    View in: PubMed
    Score: 0.031
  29. Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid. 2014 Jul; 24(7):1096-106.
    View in: PubMed
    Score: 0.030
  30. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist. 2014 May; 19(5):477-82.
    View in: PubMed
    Score: 0.030
  31. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014 Jun; 99(6):2086-94.
    View in: PubMed
    Score: 0.030
  32. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013 Dec; 169(6):891-899.
    View in: PubMed
    Score: 0.029
  33. Adrenal ganglioneuroma: features and outcomes of 27 cases at a referral cancer centre. Clin Endocrinol (Oxf). 2014 Mar; 80(3):342-7.
    View in: PubMed
    Score: 0.029
  34. Random postoperative day-3 cortisol concentration as a predictor of hypothalamic-pituitary-adrenal axis integrity after transsphenoidal surgery. Endocr Pract. 2011 Sep-Oct; 17(5):717-26.
    View in: PubMed
    Score: 0.025
  35. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience. Cancer. 2011 Oct 01; 117(19):4381-9.
    View in: PubMed
    Score: 0.024
  36. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005.
    View in: PubMed
    Score: 0.024
  37. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011 Mar; 96(3):717-25.
    View in: PubMed
    Score: 0.024
  38. A catecholamine crisis on Mount Kilimanjaro: a hypoxia effect? J Travel Med. 2010 Nov-Dec; 17(6):424-6.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.